<!DOCTYPE article
PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD v1.1d2 20140930//EN" "JATS-archivearticle1.dtd">
<article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" article-type="review-article"><?properties open_access?><?DTDIdentifier.IdentifierValue -//Springer-Verlag//DTD A++ V2.4//EN?><?DTDIdentifier.IdentifierType public?><?SourceDTD.DTDName A++V2.4.dtd?><?SourceDTD.Version 2.4?><?ConverterInfo.XSLTName springer2nlmx2.xsl?><?ConverterInfo.Version 2?><front><journal-meta><journal-id journal-id-type="nlm-ta">Theor Biol Med Model</journal-id><journal-id journal-id-type="iso-abbrev">Theor Biol Med Model</journal-id><journal-title-group><journal-title>Theoretical Biology &#x00026; Medical Modelling</journal-title></journal-title-group><issn pub-type="epub">1742-4682</issn><publisher><publisher-name>BioMed Central</publisher-name><publisher-loc>London</publisher-loc></publisher></journal-meta><article-meta><article-id pub-id-type="pmid">25252828</article-id><article-id pub-id-type="publisher-id">489</article-id><article-id pub-id-type="doi">10.1186/1742-4682-11-41</article-id><article-categories><subj-group subj-group-type="heading"><subject>Review</subject></subj-group></article-categories><title-group><article-title>Mathematical modeling of multi-drugs therapy: a challenge for determining the optimal combinations of antiviral drugs</article-title></title-group><contrib-group><contrib contrib-type="author"><name><surname>Koizumi</surname><given-names>Yoshiki</given-names></name><address><email>koizumi.yoshi@gmail.com</email></address><xref ref-type="aff" rid="Aff2"/></contrib><contrib contrib-type="author" corresp="yes"><name><surname>Iwami</surname><given-names>Shingo</given-names></name><address><email>siwami@kyushu-u.org</email></address><xref ref-type="aff" rid="Aff3"/></contrib><aff id="Aff2"><label/>School of Medicine, College of Medical, Pharmaceutical and Health Sciences, Kanazawa University, 13-1 Takaramachi, Kanazawa-shi, Ishikawa, 920-8640 Japan </aff><aff id="Aff3"><label/>Department of Biology, Faculty of Sciences, Kyushu University, 6-10-1 Hakozaki, Higashi-ku, Fukuoka, 812-8581 Japan </aff></contrib-group><pub-date pub-type="epub"><day>25</day><month>9</month><year>2014</year></pub-date><pub-date pub-type="pmc-release"><day>25</day><month>9</month><year>2014</year></pub-date><pub-date pub-type="collection"><year>2014</year></pub-date><volume>11</volume><elocation-id>41</elocation-id><history><date date-type="received"><day>7</day><month>6</month><year>2014</year></date><date date-type="accepted"><day>15</day><month>9</month><year>2014</year></date></history><permissions><copyright-statement>&#x000a9; Koizumi and Iwami; licensee BioMed Central Ltd. 2014</copyright-statement><license license-type="open-access"><license-p>This article is published under license to BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons Attribution License (<ext-link ext-link-type="uri" xlink:href="http://creativecommons.org/licenses/by/4.0">http://creativecommons.org/licenses/by/4.0</ext-link>), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly credited. The Creative Commons Public Domain Dedication waiver (<ext-link ext-link-type="uri" xlink:href="http://creativecommons.org/publicdomain/zero/1.0/">http://creativecommons.org/publicdomain/zero/1.0/</ext-link>) applies to the data made available in this article, unless otherwise stated.</license-p></license></permissions><abstract id="Abs1"><p>In the current era of antiviral drug therapy, combining multiple drugs is a primary approach for improving antiviral effects, reducing the doses of individual drugs, relieving the side effects of strong antiviral drugs, and preventing the emergence of drug-resistant viruses. Although a variety of new drugs have been developed for HIV, HCV and influenza virus, the optimal combinations of multiple drugs are incompletely understood. To optimize the benefits of multi-drugs combinations, we must investigate the interactions between the combined drugs and their target viruses. Mathematical models of viral infection dynamics provide an ideal tool for this purpose. Additionally, whether drug combinations computed by these models are synergistic can be assessed by two prominent drug combination theories, Loewe additivity and Bliss independence. By combining the mathematical modeling of virus dynamics with drug combination theories, we could show the principles by which drug combinations yield a synergistic effect. Here, we describe the theoretical aspects of multi-drugs therapy and discuss their application to antiviral research.</p></abstract><kwd-group xml:lang="en"><title>Keywords</title><kwd>Antiviral therapy</kwd><kwd>Mathematical modeling</kwd><kwd>Drug combination theory</kwd><kwd>Virus dynamics</kwd></kwd-group><custom-meta-group><custom-meta><meta-name>issue-copyright-statement</meta-name><meta-value>&#x000a9; The Author(s) 2014</meta-value></custom-meta></custom-meta-group></article-meta></front><body><sec id="Sec1"><title>Background</title><p>Several landmark mathematical modeling studies of anti-retroviral therapy were reported in 1995
[<xref ref-type="bibr" rid="CR1">1</xref>&#x02013;<xref ref-type="bibr" rid="CR4">4</xref>]. Thereafter, mathematical modeling has provided quantitative insights into antiviral drugs targeting HIV
[<xref ref-type="bibr" rid="CR5">5</xref>&#x02013;<xref ref-type="bibr" rid="CR13">13</xref>], HCV
[<xref ref-type="bibr" rid="CR14">14</xref>&#x02013;<xref ref-type="bibr" rid="CR18">18</xref>], HBV
[<xref ref-type="bibr" rid="CR19">19</xref>, <xref ref-type="bibr" rid="CR20">20</xref>] and influenza virus
[<xref ref-type="bibr" rid="CR21">21</xref>, <xref ref-type="bibr" rid="CR22">22</xref>]. These studies have elucidated the key steps of viral replication cycles and viral infection dynamics, such as the half-life of viruses and how viruses replicate in cells (reviewed in
[<xref ref-type="bibr" rid="CR23">23</xref>&#x02013;<xref ref-type="bibr" rid="CR27">27</xref>]). Although mathematical viral models could also search for drug combinations that improve antiviral effects and prevent the emergence of drug-resistant viruses, this potential of viral modeling has yet to be properly explored. Multi-drug administration is a standard treatment for HIV and HCV infection, and is also required in HBV and influenza. The established combination drug therapy for HIV, known as highly active anti-retroviral therapy (HAART), remains prohibitively expensive in developing countries. Additionally, HIV patients receiving long-term HAART may experience severe side effects such as lipodystrophy, hepatotoxicity, renal dysfunction, peripheral neuropathy and cardiovascular diseases (reviewed in
[<xref ref-type="bibr" rid="CR28">28</xref>]). By optimizing drug combinations, we could reduce the doses of individual drugs, thereby lowering the cost of treatment, reducing side effects, enhancing the antiviral effects and reducing the risk of drug-resistant viruses.</p><p>To accelerate the above benefits of drug combinations, we need to know whether or not a drug combination exerts a synergistic effect (reviewed in
[<xref ref-type="bibr" rid="CR29">29</xref>, <xref ref-type="bibr" rid="CR30">30</xref>]). A non-synergistic drug combination requires a larger than expected dose to achieve a regular antiviral effect. Although multi-drug therapy is standard practice, the complexity of the combined drugs&#x02019; responses is improperly understood, and rendered counter-intuitive by drug absorption, distribution, metabolism, and excretion through drug transporters
[<xref ref-type="bibr" rid="CR28">28</xref>]. To overcome these difficulties, comprehensive trials (or experiments) of various combinations and doses of drugs have been required. The combined effect has been investigated by empirical methods such as Loewe additivity
[<xref ref-type="bibr" rid="CR29">29</xref>, <xref ref-type="bibr" rid="CR31">31</xref>] and Bliss independence
[<xref ref-type="bibr" rid="CR29">29</xref>, <xref ref-type="bibr" rid="CR32">32</xref>]. Both theories have evolved from pharmacological research, and are used to classify combination effects as synergistic, additive or antagonistic
[<xref ref-type="bibr" rid="CR29">29</xref>, <xref ref-type="bibr" rid="CR33">33</xref>, <xref ref-type="bibr" rid="CR34">34</xref>]. These empirical frameworks have become widely accepted in pharmacology and have provided quantitative insight into drug combinations. However, because their underlying mechanics are unknown, the frameworks cannot provide reasons for a given combination effect (e.g. why is this drug combination additive, whereas that combination is antagonistic?). Showing the mechanisms of drug combination effects is expected to remarkably advance the development of multicomponent therapeutics. Thus, in addition to judging drug combination effects, knowledge of the mechanism is crucial to fundamental antiviral research.</p><p>Here we discuss two primary concepts of drug combination theory: Loewe additivity and Bliss independence. We apply these models to viral replication in a host cell, and discuss their utility for understanding two-drug interactions and viral dynamics. Finally, we discuss how drug combination theory might be applied to cancer chemotherapies and antiviral therapies. Combining mathematical models of viral replication with drug combination theory, we can establish an efficient framework for optimizing drug combinations.</p><sec id="Sec2"><title>Basic drug combination theory: Loewe additivity</title><p>Loewe additivity is regarded as a primary criterion for evaluating drug combination effects
[<xref ref-type="bibr" rid="CR29">29</xref>]. To conceptualize Loewe additivity, let us consider the simplest situation, in which a combination of drugs A and B has a synergistic, additive or antagonistic effect. If the effect is additive, the Loewe additivity is defined as
[<xref ref-type="bibr" rid="CR31">31</xref>]:
<disp-formula id="Equ1"><label>1</label><graphic xlink:href="12976_2014_489_Equ1_HTML.gif" position="anchor"/></disp-formula></p><p>where
<inline-formula id="IEq1"><inline-graphic xlink:href="12976_2014_489_IEq1_HTML.gif"/></inline-formula> and
<inline-formula id="IEq2"><inline-graphic xlink:href="12976_2014_489_IEq2_HTML.gif"/></inline-formula> are the concentrations of drugs A and B respectively in the combined dose, and <italic>C</italic><sub><italic>A</italic></sub> and <italic>C</italic><sub><italic>B</italic></sub> are the respective concentrations of drugs A and B that produce the same effect as the drug combination. That is, the Loewe additivity specifies the concentration ratio of a single drug and its combination with another drug. Note that Loewe additivity assumes that two drugs target the same molecule or pathway. If two drugs do not mutually interact, they can be related through the combination index (<italic>CI</italic>) based on the mass action law derived by Chou and Talalay
[<xref ref-type="bibr" rid="CR35">35</xref>]:
<disp-formula id="Equ2"><label>2</label><graphic xlink:href="12976_2014_489_Equ2_HTML.gif" position="anchor"/></disp-formula></p><p>where the right hand side of Eq. (<xref rid="Equ2" ref-type="">2</xref>) is identical to the left side of Eq. (<xref rid="Equ1" ref-type="">1</xref>). When CI&#x02009;&#x0003c;&#x02009;1, the relationship is synergetic, when CI&#x02009;=&#x02009;1, it is additive, and when CI&#x02009;&#x0003e;&#x02009;1, it is antagonistic. For example, suppose that 4&#x000a0;&#x003bc;M of drug A and 5&#x000a0;&#x003bc;M of drug B exert the same effect as a combination of 1&#x000a0;&#x003bc;M of A and 2&#x000a0;&#x003bc;M of B. Substituting these concentrations into Eq. (<xref rid="Equ2" ref-type="">2</xref>), we obtain <italic>CI</italic>&#x02009;=&#x02009;0.65 (=1/4&#x02009;+&#x02009;2/5&#x02009;&#x0003c;&#x02009;1), implying that the drug combination is synergistic. Note that the <italic>CI</italic> does not express the extent of synergy or antagonism; it is merely a criterion that separates the two behaviors without quantifying them.</p><p>To evaluate a drug combination effect by the <italic>CI</italic>, we require dose&#x02013;response curves of drugs A and B, from which we can determine
<inline-formula id="IEq3"><inline-graphic xlink:href="12976_2014_489_IEq3_HTML.gif"/></inline-formula> and
<inline-formula id="IEq4"><inline-graphic xlink:href="12976_2014_489_IEq4_HTML.gif"/></inline-formula>. The effect of a single drug <italic>E</italic> is modeled by the Hill function as follows:
<disp-formula id="Equ3"><label>3</label><graphic xlink:href="12976_2014_489_Equ3_HTML.gif" position="anchor"/></disp-formula></p><p>where <italic>E</italic><sub><italic>max</italic></sub> is the maximum effect, <italic>c</italic> is the drug concentration, <italic>h</italic> is the Hill coefficient that determines the steepness of the dose&#x02013;response curve, and <italic>IC</italic><sub>50</sub> is the concentration at which <italic>E</italic> exerts 50% of its maximum effect. Substituting Eq. (<xref rid="Equ3" ref-type="">3</xref>) into Eq. (<xref rid="Equ1" ref-type="">1</xref>) and rearranging in the case of <italic>E</italic><sub><italic>max</italic></sub>&#x02009;=&#x02009;1, we obtain:
<disp-formula id="Equ4"><label>4</label><graphic xlink:href="12976_2014_489_Equ4_HTML.gif" position="anchor"/></disp-formula></p><p>Numerically solving Eq. (<xref rid="Equ4" ref-type="">4</xref>) for <italic>E</italic>, we can predict the additive effect at any drug concentrations
<inline-formula id="IEq5"><inline-graphic xlink:href="12976_2014_489_IEq5_HTML.gif"/></inline-formula> and
<inline-formula id="IEq6"><inline-graphic xlink:href="12976_2014_489_IEq6_HTML.gif"/></inline-formula>[<xref ref-type="bibr" rid="CR35">35</xref>, <xref ref-type="bibr" rid="CR36">36</xref>]. The following section explains an example of applying Loewe additivity to estimate rational drug combinations and optimal doses.</p></sec><sec id="Sec3"><title>Application of Loewe additivity for estimating rational drug combinations and optimal doses</title><p>We here explain the usefulness of combining the Loewe additivity with mathematical modeling of hepatitis C virus (HCV) replication. The aim is to optimize the antiviral drug combination. Combining multiple drugs such as interferon-&#x003b1; and ribavirin is a standard therapy for enhancing the antiviral effects and reducing the risk of drug-resistant viruses. However, the conventional anti-HCV drugs fail to eradicate HCV genotype 1 in about 40% patients and may cause severe side effects. To overcome these problems, researchers have developed and administered direct acting antiviral (DAA) drugs that target viral-specific proteins such as viral proteases, as adjuncts to conventional anti-HCV drugs. To understand the principle behind optimal drug combinations and doses, we focused on the essential features of HCV replication and the mechanisms of the antiviral drugs (Figure&#x000a0;
<xref rid="Fig1" ref-type="fig">1</xref>A). Using previous mathematical models of HCV replication in a host cell
[<xref ref-type="bibr" rid="CR37">37</xref>&#x02013;<xref ref-type="bibr" rid="CR40">40</xref>], a modified mathematical model accounting for the mechanisms of drug actions would quantitatively simulate the anti-HCV effects at any dose of a drug combination. The effects of the drug combination at specific doses could then be evaluated by the Loewe additivity. In this way, we could estimate the synergistic dose point of a drug combination that enhances the anti-HCV effects (Figure&#x000a0;
<xref rid="Fig1" ref-type="fig">1</xref>B). The above analysis could predict the optimal drug combination that both reduces the total dose of each drug and enhances their anti-HCV effects.<fig id="Fig1"><label>Figure 1</label><caption><p>
<bold>Estimating the optimal drug combination from the mechanism of drug effects on viral replication. A)</bold> Conceptual diagram showing the effects of two anti-HCV drug effects on HCV replication. Drug A inhibits virus release, and drug B inhibits the production of viral polymerase. To calculate the effect of co-administered A and B on HCV production, the dynamics of each viral component during the replication are expressed by differential equations
[<xref ref-type="bibr" rid="CR37">37</xref>&#x02013;<xref ref-type="bibr" rid="CR40">40</xref>]. The presence of both drugs decreases the parameters, a production rate of viral proteins and a releasing rate of virions. <bold>B)</bold> Estimation of the optimal dose point in a drug combination. Each point (corresponding to a specific dose) denotes the difference between the effects of the combined drugs obtained by modeling the viral dynamics and the additive effects calculated by Loewe additivity. A positive (red) difference indicates that the drug combination surpasses the expected additive effect. At such synergistic dose points, the antiviral effect can be achieved by administering the drug in combination at doses below the single drug dose (the synergistic point).</p></caption><graphic xlink:href="12976_2014_489_Fig1_HTML" id="d30e472"/></fig></p></sec><sec id="Sec4"><title>The alternative drug combination theory: Bliss independence</title><p>Bliss independence is the other major criterion for clarifying drug combination effects
[<xref ref-type="bibr" rid="CR32">32</xref>]. Bliss independence defines the expectation of a combined drug effect, calculated by multiplying the probabilities of the individual drugs. It assumes that each drug independently targets a different stage of viral replication via a different mechanism, with no interaction between the drug actions. Bliss independence expresses the unaffected probability of a two-drug combination <italic>U</italic><sub><italic>AB</italic></sub> as the product of the unaffected probabilities <italic>U</italic><sub><italic>A</italic></sub> and <italic>U</italic><sub><italic>B</italic></sub> of drugs A and B:
<disp-formula id="Equ5"><label>5</label><graphic xlink:href="12976_2014_489_Equ5_HTML.gif" position="anchor"/></disp-formula></p><p>Intuitively, Eq. (<xref rid="Equ5" ref-type="">5</xref>) implies that targets bypassed by drug A will be intercepted by drug B. The total probability of missed targets is obtained by multiplying the probabilities of the unaffected targets. Substituting <italic>U</italic> by&#x000a0;1&#x02009;-&#x02009;<italic>P</italic>, where <italic>P</italic> denotes the probability of an intercepted target, Eq. (<xref rid="Equ5" ref-type="">5</xref>) can be expressed as (1&#x02009;-&#x02009;<italic>P</italic><sub><italic>AB</italic></sub>)&#x02009;=&#x02009;(1&#x02009;-&#x02009;<italic>P</italic><sub><italic>A</italic></sub>)&#x02009;&#x000d7;&#x02009;(1&#x02009;-&#x02009;<italic>P</italic><sub><italic>B</italic></sub>), or
<disp-formula id="Equ6"><label>6</label><graphic xlink:href="12976_2014_489_Equ6_HTML.gif" position="anchor"/></disp-formula></p><p>If the combined effect of the single drug doses is consistent with Eq. (<xref rid="Equ6" ref-type="">6</xref>), this drug combination is evaluated as additive according to the Bliss independence measure. For instance, suppose that drugs A and B exhibit 50% and 60% inhibition, respectively. The Bliss independence predicts that drugs A and B will exert a combined inhibitory effect of 80%, calculated as <italic>P</italic><sub><italic>AB</italic></sub>&#x02009;=&#x02009;0.5&#x02009;+&#x02009;0.6&#x02009;-&#x02009;0.5&#x02009;&#x000d7;&#x02009;0.6&#x02009;=&#x02009;0.8.</p><p>Unlike the Loewe additivity, the Bliss independence can evaluate the effect of a drug combination without requiring dose&#x02013;response curves of the single drugs. If we attempt to assess a drug combination by the Loewe additivity, we must measure the effects at several single doses for constructing the dose&#x02013;response curve. In contrast, the Bliss independence can assess the effects of a drug combination from a single point. Thus, the Bliss independence is useful if experimental data are limited. Additionally, in specific cases, the Bliss independence and Loewe additivity can be rendered equivalent using the Hill function Eq. (<xref rid="Equ3" ref-type="">3</xref>)
[<xref ref-type="bibr" rid="CR41">41</xref>]. The following section explains an example of applying Bliss independence to quantifying the antiviral effects of intrinsic factors on HIV replication.</p></sec><sec id="Sec5"><title>Quantifying the antiviral effects of APOBEC3G on HIV replication by Bliss independence</title><p>The Bliss independence measure can predict antiviral effects as well as evaluate drug combinations. To illustrate this idea, we estimate the anti-HIV effect of a well-known antiviral host factor by Bliss independence
[<xref ref-type="bibr" rid="CR42">42</xref>]. Apolipoprotein B mRNA editing enzyme catalytic polypeptide-like 3G (APOBEC3G) suppresses HIV replication in cells by two main mechanisms: (1) inhibiting viral reverse transcriptase and (2) mutating cytidine (C) to uracil (U) in viral DNA by cytidine deaminase activity (Figure&#x000a0;
<xref rid="Fig2" ref-type="fig">2</xref>A). Although the anti-HIV effect of reverse transcriptase inhibition can be measured using a mutated APOBEC3G (with its C-to-U activity removed) (Figure&#x000a0;
<xref rid="Fig2" ref-type="fig">2</xref>A), the extent to which the mutation itself inhibits HIV replication cannot be experimentally determined. To quantify the anti-HIV effect of C-to-U mutation by APOBEC 3G, we can use Bliss independence to model the unaffected fractions of viral infectivity of wild-type (WT) and mutant APOBEC3G, denoted <italic>f</italic><sub><italic>WT</italic></sub> and <italic>f</italic><sub><italic>CI</italic></sub> respectively, in terms of the unaffected fractions of viral infectivity by reverse transcription inhibition and C-to-U mutation, <italic>f</italic><sub><italic>RT</italic></sub> and <italic>f</italic><sub><italic>Mu</italic></sub>, as follows:<fig id="Fig2"><label>Figure 2</label><caption><p>
<bold>Estimating the antiviral effects of C-to-U mutation by APOBEC3G on HIV production. A)</bold> Mechanism of APOBEC3G inhibition in HIV replication. <bold>B)</bold> Quantification of antiviral effects of mutant APOBEC3G on HIV infection. HIV production reduces with increasing expression of APOBEC3G (dots: experimental data, solid lines: theoretical predictions, purple: WT APOBEC3G, blue: mutated APOBEC3G). Red dotted line shows the expected anti-HIV effect of C-to-U mutation activity, determined by Bliss independence.</p></caption><graphic xlink:href="12976_2014_489_Fig2_HTML" id="d30e618"/></fig></p><p><disp-formula id="Equa"><graphic xlink:href="12976_2014_489_Equa_HTML.gif" position="anchor"/></disp-formula></p><p>and
<disp-formula id="Equb"><graphic xlink:href="12976_2014_489_Equb_HTML.gif" position="anchor"/></disp-formula></p><p>where <italic>x</italic> is the expression level of APOBEC3G, <italic>h</italic><sub><italic>RT</italic></sub> and <italic>h</italic><sub><italic>Mu</italic></sub> are Hill coefficients, and
<inline-formula id="IEq7"><inline-graphic xlink:href="12976_2014_489_IEq7_HTML.gif"/></inline-formula> and
<inline-formula id="IEq8"><inline-graphic xlink:href="12976_2014_489_IEq8_HTML.gif"/></inline-formula> are the expression levels required to achieve 50% inhibition by reverse transcription inhibition and C-to-U mutation, respectively. We estimated 4 parameters (<italic>h</italic><sub><italic>RT</italic></sub>, <italic>h</italic><sub><italic>Mu</italic></sub>,
<inline-formula id="IEq9"><inline-graphic xlink:href="12976_2014_489_IEq9_HTML.gif"/></inline-formula>, and
<inline-formula id="IEq10"><inline-graphic xlink:href="12976_2014_489_IEq10_HTML.gif"/></inline-formula>) by fitting to experimental data of WT and mutated APOBEC3G (Figure&#x000a0;
<xref rid="Fig2" ref-type="fig">2</xref>B). Thus, the anti-HIV effect of C-to-U mutation by APOBEC3G can be quantitatively estimated by a Bliss independence-based modeling approach.</p></sec><sec id="Sec6"><title>Potential applications of drug combination theory</title><p>The Loewe additivity and Bliss independence form the basis of sophisticated protocols for assessing drug combinations, especially in cancer-targeted chemotherapy
[<xref ref-type="bibr" rid="CR33">33</xref>, <xref ref-type="bibr" rid="CR34">34</xref>]. Research on biological network systems, as well as the biochemical characteristics of drugs, has also unraveled the mechanisms by which drug combinations produce synergistic effects (reviewed in
[<xref ref-type="bibr" rid="CR41">41</xref>, <xref ref-type="bibr" rid="CR43">43</xref>&#x02013;<xref ref-type="bibr" rid="CR45">45</xref>]). Such research is important because (1) it facilitates rational drug discovery and (2) it predicts unknown connectivities in biological networks. Regarding the first point, the effects of a developing drug combined with conventional drugs are maximized by investigating biological networks, and rational drug targets are decided. For example, using computational modeling of cancer signaling networks and animal experiments, Kirouac <italic>et al.</italic>[<xref ref-type="bibr" rid="CR46">46</xref>] identified the optimal inhibitor combination for suppressing the growth of <italic>ERBB2</italic>-amplified breast cancer. They adopted Bliss independence as a synergy criterion. Supplementing this computational approach with experimental data is useful for developing theoretically effective novel drugs. Regarding point (2), the biological networks of signaling pathways constructed by various components can be predicted from the dose&#x02013;response shapes of drug combinations (reviewed in
[<xref ref-type="bibr" rid="CR47">47</xref>]). Lehar <italic>et al.</italic>[<xref ref-type="bibr" rid="CR48">48</xref>] used several drug combination criteria, including Loewe additivity and Bliss independence, to connect biological components from the results of cellular responses to chemical combinations. This approach assumes that the dose&#x02013;response shape of a drug combination depends on how drug targets are connected in a biological system.</p><p>The above research potentially benefits not only cancer chemotherapy, but also antiviral therapy development. For instance, Owens <italic>et al.</italic>[<xref ref-type="bibr" rid="CR49">49</xref>] showed how HCV replication responds to chemical combinations that inhibit some enzymes involved in the sterol biosynthesis pathway. Supplementing computational simulation with <italic>in vitro</italic> experiments, they identified a rational inhibitor combination as a novel drug candidate. Mathematical models of HCV dynamics during drug therapy have also been investigated at the intracellular level
[<xref ref-type="bibr" rid="CR18">18</xref>], the intercellular level
[<xref ref-type="bibr" rid="CR14">14</xref>&#x02013;<xref ref-type="bibr" rid="CR17">17</xref>, <xref ref-type="bibr" rid="CR50">50</xref>, <xref ref-type="bibr" rid="CR51">51</xref>], and on a scale encompassing both levels
[<xref ref-type="bibr" rid="CR51">51</xref>&#x02013;<xref ref-type="bibr" rid="CR54">54</xref>]. These studies have quantitatively elucidated the properties of anti-HCV drugs such as interferon and protease inhibitors. Furthermore, by inputting clinical data to a mathematical model of HCV dynamics, Rong <italic>et al.</italic>[<xref ref-type="bibr" rid="CR55">55</xref>] derived a mechanism by which drug-resistant viruses can rapidly emerge during single-drug therapy. Applying drug combination theories to these studies, mathematical models of HCV dynamics could be used to optimize the anti-HCV drug dosage and combination, thereby enhancing the anti-viral effect and reducing the risk of drug-resistant viruses (Figure&#x000a0;
<xref rid="Fig3" ref-type="fig">3</xref>).<fig id="Fig3"><label>Figure 3</label><caption><p>
<bold>Concept of integrating drug combination theory and viral dynamics.</bold> The effect of a drug combination calculated by mathematical modeling of viral dynamics could be assessed by the Loewe additivity and Bliss independence. This approach could improve antiviral therapy by predicting the effect of a drug combination <italic>in vivo</italic> and <italic>in vitro</italic>, estimating the optimal drug dosage and combination, and discovering how the drugs interact.</p></caption><graphic xlink:href="12976_2014_489_Fig3_HTML" id="d30e777"/></fig></p></sec></sec><sec id="Sec7" sec-type="conclusions"><title>Conclusion</title><p>We have reviewed two major drug combination theories, Loewe additivity and Bliss independence, and discussed how combining these theories with mathematical modeling of viral dynamics might assist antiviral drug therapy. In addition, we have proposed an efficient framework for optimizing drug combinations and quantifying the anti-viral effect. Based on previous studies of computational virology, the integration of drug combination theory and dynamic modeling is a new approach with great potential for showing viral responses to drug combinations, and accelerating novel antiviral drug discovery.</p></sec></body><back><fn-group><fn><p><bold>Competing interests</bold></p><p>The authors declare that they have no competing interests.</p></fn><fn><p><bold>Authors&#x02019; contributions</bold></p><p>Conceived and designed the study: YK SI. Wrote the paper: YK SI. Both authors read and approved the final manuscript.</p></fn></fn-group><ack><p>This research is partly supported by a Grants-in-Aid for Young Scientists B25800092 (to S.I.) from the Japan Society for the Promotion of Science (JSPS); the Kyushu University Interdisciplinary Programs in Education and Projects in Research Development (to S.I.); the Aihara Innovative Mathematical Modeling Project, JSPS through the &#x0201c;Funding Program for World-Leading Innovative R &#x00026; D on Science and Technology (FIRST program)&#x0201d;, initiated by Council for Science and Technology Policy (to S.I.).</p></ack><ref-list id="Bib1"><title>References</title><ref id="CR1"><label>1.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ho</surname><given-names>DD</given-names></name><name><surname>Neumann</surname><given-names>AU</given-names></name><name><surname>Perelson</surname><given-names>AS</given-names></name><name><surname>Chen</surname><given-names>W</given-names></name><name><surname>Leonard</surname><given-names>JM</given-names></name><name><surname>Markowitz</surname><given-names>M</given-names></name></person-group><article-title>Rapid turnover of plasma virions and CD4 lymphocytes in HIV-1 infection</article-title><source>Nature</source><year>1995</year><volume>373</volume><fpage>123</fpage><lpage>126</lpage><pub-id pub-id-type="doi">10.1038/373123a0</pub-id><?supplied-pmid 7816094?><pub-id pub-id-type="pmid">7816094</pub-id></element-citation></ref><ref id="CR2"><label>2.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Wei</surname><given-names>X</given-names></name><name><surname>Ghosh</surname><given-names>SK</given-names></name><name><surname>Taylor</surname><given-names>ME</given-names></name><name><surname>Johnson</surname><given-names>VA</given-names></name><name><surname>Emini</surname><given-names>EA</given-names></name><name><surname>Deutsch</surname><given-names>P</given-names></name><name><surname>Lifson</surname><given-names>JD</given-names></name><name><surname>Bonhoeffer</surname><given-names>S</given-names></name><name><surname>Nowak</surname><given-names>MA</given-names></name><name><surname>Hahn</surname><given-names>BH</given-names></name></person-group><article-title>Viral dynamics in human immunodeficiency virus type 1 infection</article-title><source>Nature</source><year>1995</year><volume>373</volume><fpage>117</fpage><lpage>122</lpage><pub-id pub-id-type="doi">10.1038/373117a0</pub-id><?supplied-pmid 7529365?><pub-id pub-id-type="pmid">7529365</pub-id></element-citation></ref><ref id="CR3"><label>3.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Nowak</surname><given-names>MA</given-names></name><name><surname>Bonhoeffer</surname><given-names>S</given-names></name><name><surname>Loveday</surname><given-names>C</given-names></name><name><surname>Balfe</surname><given-names>P</given-names></name><name><surname>Semple</surname><given-names>M</given-names></name><name><surname>Kaye</surname><given-names>S</given-names></name><name><surname>Tenant-Flowers</surname><given-names>M</given-names></name><name><surname>Tedder</surname><given-names>R</given-names></name></person-group><article-title>HIV results in the frame. Results confirmed</article-title><source>Nature</source><year>1995</year><volume>375</volume><fpage>193</fpage><pub-id pub-id-type="doi">10.1038/375193a0</pub-id><?supplied-pmid 7746311?><pub-id pub-id-type="pmid">7746311</pub-id></element-citation></ref><ref id="CR4"><label>4.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Coffin</surname><given-names>JM</given-names></name></person-group><article-title>HIV population dynamics in vivo: implications for genetic variation, pathogenesis, and therapy</article-title><source>Science</source><year>1995</year><volume>267</volume><fpage>483</fpage><lpage>489</lpage><pub-id pub-id-type="doi">10.1126/science.7824947</pub-id><?supplied-pmid 7824947?><pub-id pub-id-type="pmid">7824947</pub-id></element-citation></ref><ref id="CR5"><label>5.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Perelson</surname><given-names>AS</given-names></name><name><surname>Neumann</surname><given-names>AU</given-names></name><name><surname>Markowitz</surname><given-names>M</given-names></name><name><surname>Leonard</surname><given-names>JM</given-names></name><name><surname>Ho</surname><given-names>DD</given-names></name></person-group><article-title>HIV-1 dynamics in vivo: virion clearance rate, infected cell life-span, and viral generation time</article-title><source>Science</source><year>1996</year><volume>271</volume><fpage>1582</fpage><lpage>1586</lpage><pub-id pub-id-type="doi">10.1126/science.271.5255.1582</pub-id><?supplied-pmid 8599114?><pub-id pub-id-type="pmid">8599114</pub-id></element-citation></ref><ref id="CR6"><label>6.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Wein</surname><given-names>LM</given-names></name><name><surname>Zenios</surname><given-names>SA</given-names></name><name><surname>Nowak</surname><given-names>MA</given-names></name></person-group><article-title>Dynamic multidrug therapies for HIV: a control theoretic approach</article-title><source>J Theor Biol</source><year>1997</year><volume>185</volume><fpage>15</fpage><lpage>29</lpage><pub-id pub-id-type="doi">10.1006/jtbi.1996.0253</pub-id><?supplied-pmid 9093552?><pub-id pub-id-type="pmid">9093552</pub-id></element-citation></ref><ref id="CR7"><label>7.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Perelson</surname><given-names>AS</given-names></name><name><surname>Essunger</surname><given-names>P</given-names></name><name><surname>Cao</surname><given-names>Y</given-names></name><name><surname>Vesanen</surname><given-names>M</given-names></name><name><surname>Hurley</surname><given-names>A</given-names></name><name><surname>Saksela</surname><given-names>K</given-names></name><name><surname>Markowitz</surname><given-names>M</given-names></name><name><surname>Ho</surname><given-names>DD</given-names></name></person-group><article-title>Decay characteristics of HIV-1-infected compartments during combination therapy</article-title><source>Nature</source><year>1997</year><volume>387</volume><fpage>188</fpage><lpage>191</lpage><pub-id pub-id-type="doi">10.1038/387188a0</pub-id><?supplied-pmid 9144290?><pub-id pub-id-type="pmid">9144290</pub-id></element-citation></ref><ref id="CR8"><label>8.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Notermans</surname><given-names>DW</given-names></name><name><surname>Goudsmit</surname><given-names>J</given-names></name><name><surname>Danner</surname><given-names>SA</given-names></name><name><surname>de Wolf</surname><given-names>F</given-names></name><name><surname>Perelson</surname><given-names>AS</given-names></name><name><surname>Mittler</surname><given-names>J</given-names></name></person-group><article-title>Rate of HIV-1 decline following antiretroviral therapy is related to viral load at baseline and drug regimen</article-title><source>AIDS</source><year>1998</year><volume>12</volume><fpage>1483</fpage><lpage>1490</lpage><pub-id pub-id-type="doi">10.1097/00002030-199812000-00010</pub-id><?supplied-pmid 9727569?><pub-id pub-id-type="pmid">9727569</pub-id></element-citation></ref><ref id="CR9"><label>9.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Wein</surname><given-names>LM</given-names></name><name><surname>D&#x02019;Amato</surname><given-names>RM</given-names></name><name><surname>Perelson</surname><given-names>AS</given-names></name></person-group><article-title>Mathematical analysis of antiretroviral therapy aimed at HIV-1 eradication or maintenance of low viral loads</article-title><source>J Theor Biol</source><year>1998</year><volume>192</volume><fpage>81</fpage><lpage>98</lpage><pub-id pub-id-type="doi">10.1006/jtbi.1997.0622</pub-id><?supplied-pmid 9628841?><pub-id pub-id-type="pmid">9628841</pub-id></element-citation></ref><ref id="CR10"><label>10.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Di Mascio</surname><given-names>M</given-names></name><name><surname>Markowitz</surname><given-names>M</given-names></name><name><surname>Louie</surname><given-names>M</given-names></name><name><surname>Hogan</surname><given-names>C</given-names></name><name><surname>Hurley</surname><given-names>A</given-names></name><name><surname>Chung</surname><given-names>C</given-names></name><name><surname>Ho</surname><given-names>DD</given-names></name><name><surname>Perelson</surname><given-names>AS</given-names></name></person-group><article-title>Viral blip dynamics during highly active antiretroviral therapy</article-title><source>J Virol</source><year>2003</year><volume>77</volume><fpage>12165</fpage><lpage>12172</lpage><pub-id pub-id-type="doi">10.1128/JVI.77.22.12165-12172.2003</pub-id><?supplied-pmid 14581553?><pub-id pub-id-type="pmid">14581553</pub-id></element-citation></ref><ref id="CR11"><label>11.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Sedaghat</surname><given-names>AR</given-names></name><name><surname>Dinoso</surname><given-names>JB</given-names></name><name><surname>Shen</surname><given-names>L</given-names></name><name><surname>Wilke</surname><given-names>CO</given-names></name><name><surname>Siliciano</surname><given-names>RF</given-names></name></person-group><article-title>Decay dynamics of HIV-1 depend on the inhibited stages of the viral life cycle</article-title><source>Proc Natl Acad Sci U S A</source><year>2008</year><volume>105</volume><fpage>4832</fpage><lpage>4837</lpage><pub-id pub-id-type="doi">10.1073/pnas.0711372105</pub-id><?supplied-pmid 18362342?><pub-id pub-id-type="pmid">18362342</pub-id></element-citation></ref><ref id="CR12"><label>12.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Shen</surname><given-names>L</given-names></name><name><surname>Rabi</surname><given-names>SA</given-names></name><name><surname>Sedaghat</surname><given-names>AR</given-names></name><name><surname>Shan</surname><given-names>L</given-names></name><name><surname>Lai</surname><given-names>J</given-names></name><name><surname>Xing</surname><given-names>S</given-names></name><name><surname>Siliciano</surname><given-names>RF</given-names></name></person-group><article-title>A critical subset model provides a conceptual basis for the high antiviral activity of major HIV drugs</article-title><source>Sci Transl Med</source><year>2011</year><volume>3</volume><fpage>91ra63</fpage><pub-id pub-id-type="doi">10.1126/scitranslmed.3002304</pub-id><?supplied-pmid 21753122?><pub-id pub-id-type="pmid">21753122</pub-id></element-citation></ref><ref id="CR13"><label>13.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Rosenbloom</surname><given-names>DIS</given-names></name><name><surname>Hill</surname><given-names>AL</given-names></name><name><surname>Rabi</surname><given-names>SA</given-names></name><name><surname>Siliciano</surname><given-names>RF</given-names></name><name><surname>Nowak</surname><given-names>MA</given-names></name></person-group><article-title>Antiretroviral dynamics determines HIV evolution and predicts therapy outcome</article-title><source>Nat Med</source><year>2012</year><volume>18</volume><fpage>1378</fpage><lpage>1385</lpage><pub-id pub-id-type="doi">10.1038/nm.2892</pub-id><?supplied-pmid 22941277?><pub-id pub-id-type="pmid">22941277</pub-id></element-citation></ref><ref id="CR14"><label>14.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Zeuzem</surname><given-names>S</given-names></name><name><surname>Schmidt</surname><given-names>JM</given-names></name><name><surname>Lee</surname><given-names>JH</given-names></name><name><surname>von Wagner</surname><given-names>M</given-names></name><name><surname>Teuber</surname><given-names>G</given-names></name><name><surname>Roth</surname><given-names>WK</given-names></name></person-group><article-title>Hepatitis C virus dynamics in vivo: effect of ribavirin and interferon alfa on viral turnover</article-title><source>Hepatology</source><year>1998</year><volume>28</volume><fpage>245</fpage><lpage>252</lpage><pub-id pub-id-type="doi">10.1002/hep.510280132</pub-id><?supplied-pmid 9657119?><pub-id pub-id-type="pmid">9657119</pub-id></element-citation></ref><ref id="CR15"><label>15.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Neumann</surname><given-names>AU</given-names></name><name><surname>Lam</surname><given-names>NP</given-names></name><name><surname>Dahari</surname><given-names>H</given-names></name><name><surname>Gretch</surname><given-names>DR</given-names></name><name><surname>Wiley</surname><given-names>TE</given-names></name><name><surname>Layden</surname><given-names>TJ</given-names></name><name><surname>Perelson</surname><given-names>AS</given-names></name></person-group><article-title>Hepatitis C viral dynamics in vivo and the antiviral efficacy of interferon-alpha therapy</article-title><source>Science</source><year>1998</year><volume>282</volume><fpage>103</fpage><lpage>107</lpage><pub-id pub-id-type="doi">10.1126/science.282.5386.103</pub-id><?supplied-pmid 9756471?><pub-id pub-id-type="pmid">9756471</pub-id></element-citation></ref><ref id="CR16"><label>16.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Dixit</surname><given-names>NM</given-names></name><name><surname>Layden-Almer</surname><given-names>JE</given-names></name><name><surname>Layden</surname><given-names>TJ</given-names></name><name><surname>Perelson</surname><given-names>AS</given-names></name></person-group><article-title>Modelling how ribavirin improves interferon response rates in hepatitis C virus infection</article-title><source>Nature</source><year>2004</year><volume>432</volume><fpage>922</fpage><lpage>924</lpage><pub-id pub-id-type="doi">10.1038/nature03153</pub-id><?supplied-pmid 15602565?><pub-id pub-id-type="pmid">15602565</pub-id></element-citation></ref><ref id="CR17"><label>17.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Dahari</surname><given-names>H</given-names></name><name><surname>Ribeiro</surname><given-names>RM</given-names></name><name><surname>Perelson</surname><given-names>AS</given-names></name></person-group><article-title>Triphasic decline of hepatitis C virus RNA during antiviral therapy</article-title><source>Hepatology</source><year>2007</year><volume>46</volume><fpage>16</fpage><lpage>21</lpage><pub-id pub-id-type="doi">10.1002/hep.21657</pub-id><?supplied-pmid 17596864?><pub-id pub-id-type="pmid">17596864</pub-id></element-citation></ref><ref id="CR18"><label>18.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Dahari</surname><given-names>H</given-names></name><name><surname>Sainz</surname><given-names>B</given-names></name><name><surname>Perelson</surname><given-names>AS</given-names></name><name><surname>Uprichard</surname><given-names>SL</given-names></name></person-group><article-title>Modeling subgenomic hepatitis C virus RNA kinetics during treatment with alpha interferon</article-title><source>J Virol</source><year>2009</year><volume>83</volume><fpage>6383</fpage><lpage>6390</lpage><pub-id pub-id-type="doi">10.1128/JVI.02612-08</pub-id><?supplied-pmid 19369346?><pub-id pub-id-type="pmid">19369346</pub-id></element-citation></ref><ref id="CR19"><label>19.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lewin</surname><given-names>SR</given-names></name><name><surname>Ribeiro</surname><given-names>RM</given-names></name><name><surname>Walters</surname><given-names>T</given-names></name><name><surname>Lau</surname><given-names>GK</given-names></name><name><surname>Bowden</surname><given-names>S</given-names></name><name><surname>Locarnini</surname><given-names>S</given-names></name><name><surname>Perelson</surname><given-names>AS</given-names></name></person-group><article-title>Analysis of hepatitis B viral load decline under potent therapy: complex decay profiles observed</article-title><source>Hepatology</source><year>2001</year><volume>34</volume><fpage>1012</fpage><lpage>1020</lpage><pub-id pub-id-type="doi">10.1053/jhep.2001.28509</pub-id><?supplied-pmid 11679973?><pub-id pub-id-type="pmid">11679973</pub-id></element-citation></ref><ref id="CR20"><label>20.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Dahari</surname><given-names>H</given-names></name><name><surname>Shudo</surname><given-names>E</given-names></name><name><surname>Ribeiro</surname><given-names>RM</given-names></name><name><surname>Perelson</surname><given-names>AS</given-names></name></person-group><article-title>Modeling complex decay profiles of hepatitis B virus during antiviral therapy</article-title><source>Hepatology</source><year>2009</year><volume>49</volume><fpage>32</fpage><lpage>38</lpage><pub-id pub-id-type="doi">10.1002/hep.22586</pub-id><?supplied-pmid 19065674?><pub-id pub-id-type="pmid">19065674</pub-id></element-citation></ref><ref id="CR21"><label>21.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Beauchemin</surname><given-names>CAA</given-names></name><name><surname>McSharry</surname><given-names>JJ</given-names></name><name><surname>Drusano</surname><given-names>GL</given-names></name><name><surname>Nguyen</surname><given-names>JT</given-names></name><name><surname>Went</surname><given-names>GT</given-names></name><name><surname>Ribeiro</surname><given-names>RM</given-names></name><name><surname>Perelson</surname><given-names>AS</given-names></name></person-group><article-title>Modeling amantadine treatment of influenza A virus in vitro</article-title><source>J Theor Biol</source><year>2008</year><volume>254</volume><fpage>439</fpage><lpage>451</lpage><pub-id pub-id-type="doi">10.1016/j.jtbi.2008.05.031</pub-id><?supplied-pmid 18653201?><pub-id pub-id-type="pmid">18653201</pub-id></element-citation></ref><ref id="CR22"><label>22.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Dobrovolny</surname><given-names>HM</given-names></name><name><surname>Gieschke</surname><given-names>R</given-names></name><name><surname>Davies</surname><given-names>BE</given-names></name><name><surname>Jumbe</surname><given-names>NL</given-names></name><name><surname>Beauchemin</surname><given-names>CAA</given-names></name></person-group><article-title>Neuraminidase inhibitors for treatment of human and avian strain influenza: A comparative modeling study</article-title><source>J Theor Biol</source><year>2011</year><volume>269</volume><fpage>234</fpage><lpage>244</lpage><pub-id pub-id-type="doi">10.1016/j.jtbi.2010.10.017</pub-id><?supplied-pmid 20970433?><pub-id pub-id-type="pmid">20970433</pub-id></element-citation></ref><ref id="CR23"><label>23.</label><element-citation publication-type="book"><person-group person-group-type="author"><name><surname>Nowak</surname><given-names>M</given-names></name><name><surname>May</surname><given-names>RM</given-names></name></person-group><source>Virus Dynamics: Mathematical Principles of Immunology and Virology</source><year>2001</year><publisher-loc>USA</publisher-loc><publisher-name>Oxford University Press</publisher-name><fpage>256</fpage></element-citation></ref><ref id="CR24"><label>24.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Perelson</surname><given-names>AS</given-names></name></person-group><article-title>Modelling viral and immune system dynamics</article-title><source>Nat Rev Immunol</source><year>2002</year><volume>2</volume><fpage>28</fpage><lpage>36</lpage><pub-id pub-id-type="doi">10.1038/nri700</pub-id><?supplied-pmid 11905835?><pub-id pub-id-type="pmid">11905835</pub-id></element-citation></ref><ref id="CR25"><label>25.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Rong</surname><given-names>L</given-names></name><name><surname>Perelson</surname><given-names>AS</given-names></name></person-group><article-title>Modeling HIV persistence, the latent reservoir, and viral blips</article-title><source>J Theor Biol</source><year>2009</year><volume>260</volume><fpage>308</fpage><lpage>331</lpage><pub-id pub-id-type="doi">10.1016/j.jtbi.2009.06.011</pub-id><?supplied-pmid 19539630?><pub-id pub-id-type="pmid">19539630</pub-id></element-citation></ref><ref id="CR26"><label>26.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Guedj</surname><given-names>J</given-names></name><name><surname>Rong</surname><given-names>L</given-names></name><name><surname>Dahari</surname><given-names>H</given-names></name><name><surname>Perelson</surname><given-names>AS</given-names></name></person-group><article-title>A perspective on modelling hepatitis C virus infection</article-title><source>J Viral Hepat</source><year>2010</year><volume>17</volume><fpage>825</fpage><lpage>833</lpage><pub-id pub-id-type="doi">10.1111/j.1365-2893.2010.01348.x</pub-id><?supplied-pmid 20723038?><pub-id pub-id-type="pmid">20723038</pub-id></element-citation></ref><ref id="CR27"><label>27.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Chatterjee</surname><given-names>A</given-names></name><name><surname>Guedj</surname><given-names>J</given-names></name><name><surname>Perelson</surname><given-names>AS</given-names></name></person-group><article-title>Mathematical modelling of HCV infection: what can it teach us in the era of direct-acting antiviral agents?</article-title><source>Antivir Ther</source><year>2012</year><volume>17</volume><fpage>1171</fpage><lpage>1182</lpage><pub-id pub-id-type="doi">10.3851/IMP2428</pub-id><?supplied-pmid 23186606?><pub-id pub-id-type="pmid">23186606</pub-id></element-citation></ref><ref id="CR28"><label>28.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hawkins</surname><given-names>T</given-names></name></person-group><article-title>Understanding and managing the adverse effects of antiretroviral therapy</article-title><source>Antiviral Res</source><year>2010</year><volume>85</volume><fpage>201</fpage><lpage>209</lpage><pub-id pub-id-type="doi">10.1016/j.antiviral.2009.10.016</pub-id><?supplied-pmid 19857521?><pub-id pub-id-type="pmid">19857521</pub-id></element-citation></ref><ref id="CR29"><label>29.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Greco</surname><given-names>WR</given-names></name><name><surname>Bravo</surname><given-names>G</given-names></name><name><surname>Parsons</surname><given-names>JC</given-names></name></person-group><article-title>The search for synergy: a critical review from a response surface perspective</article-title><source>Pharmacol Rev</source><year>1995</year><volume>47</volume><fpage>331</fpage><lpage>385</lpage><?supplied-pmid 7568331?><pub-id pub-id-type="pmid">7568331</pub-id></element-citation></ref><ref id="CR30"><label>30.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Tallarida</surname><given-names>RJ</given-names></name></person-group><article-title>Drug synergism: its detection and applications</article-title><source>J Pharmacol Exp Ther</source><year>2001</year><volume>298</volume><fpage>865</fpage><lpage>872</lpage><?supplied-pmid 11504778?><pub-id pub-id-type="pmid">11504778</pub-id></element-citation></ref><ref id="CR31"><label>31.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Loewe</surname><given-names>S</given-names></name></person-group><article-title>The problem of synergism and antagonism of combined drugs</article-title><source>Arzneimittelforschung</source><year>1953</year><volume>3</volume><fpage>285</fpage><lpage>290</lpage><?supplied-pmid 13081480?><pub-id pub-id-type="pmid">13081480</pub-id></element-citation></ref><ref id="CR32"><label>32.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Bliss</surname><given-names>CI</given-names></name></person-group><article-title>The toxicity of poisons applied jointly</article-title><source>Ann Appl Biol</source><year>1939</year><volume>26</volume><fpage>585</fpage><lpage>615</lpage><pub-id pub-id-type="doi">10.1111/j.1744-7348.1939.tb06990.x</pub-id></element-citation></ref><ref id="CR33"><label>33.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Chou</surname><given-names>TC</given-names></name></person-group><article-title>Theoretical basis, experimental design, and computerized simulation of synergism and antagonism in drug combination studies</article-title><source>Pharmacol Rev</source><year>2006</year><volume>58</volume><fpage>621</fpage><lpage>681</lpage><pub-id pub-id-type="doi">10.1124/pr.58.3.10</pub-id><?supplied-pmid 16968952?><pub-id pub-id-type="pmid">16968952</pub-id></element-citation></ref><ref id="CR34"><label>34.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Chou</surname><given-names>TC</given-names></name></person-group><article-title>Drug combination studies and their synergy quantification using the Chou-Talalay method</article-title><source>Cancer Res</source><year>2010</year><volume>70</volume><fpage>440</fpage><lpage>446</lpage><pub-id pub-id-type="doi">10.1158/0008-5472.CAN-09-1947</pub-id><?supplied-pmid 20068163?><pub-id pub-id-type="pmid">20068163</pub-id></element-citation></ref><ref id="CR35"><label>35.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Chou</surname><given-names>TC</given-names></name><name><surname>Talalay</surname><given-names>P</given-names></name></person-group><article-title>Quantitative analysis of dose-effect relationships: the combined effects of multiple drugs or enzyme inhibitors</article-title><source>Adv Enzyme Regul</source><year>1984</year><volume>22</volume><fpage>27</fpage><lpage>55</lpage><pub-id pub-id-type="doi">10.1016/0065-2571(84)90007-4</pub-id><?supplied-pmid 6382953?><pub-id pub-id-type="pmid">6382953</pub-id></element-citation></ref><ref id="CR36"><label>36.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Martinez-Irujo</surname><given-names>JJ</given-names></name><name><surname>Villahermosa</surname><given-names>ML</given-names></name><name><surname>Alberdi</surname><given-names>E</given-names></name><name><surname>Santiago</surname><given-names>E</given-names></name></person-group><article-title>A checkerboard method to evaluate interactions between drugs</article-title><source>Biochem Pharmacol</source><year>1996</year><volume>51</volume><fpage>635</fpage><lpage>644</lpage><pub-id pub-id-type="doi">10.1016/S0006-2952(95)02230-9</pub-id><?supplied-pmid 8615900?><pub-id pub-id-type="pmid">8615900</pub-id></element-citation></ref><ref id="CR37"><label>37.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Dahari</surname><given-names>H</given-names></name><name><surname>Ribeiro</surname><given-names>RM</given-names></name><name><surname>Rice</surname><given-names>CM</given-names></name><name><surname>Perelson</surname><given-names>AS</given-names></name></person-group><article-title>Mathematical modeling of subgenomic hepatitis C virus replication in Huh-7 cells</article-title><source>J Virol</source><year>2007</year><volume>81</volume><fpage>750</fpage><lpage>760</lpage><pub-id pub-id-type="doi">10.1128/JVI.01304-06</pub-id><?supplied-pmid 17035310?><pub-id pub-id-type="pmid">17035310</pub-id></element-citation></ref><ref id="CR38"><label>38.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>McLean</surname><given-names>AK</given-names></name><name><surname>Luciani</surname><given-names>F</given-names></name><name><surname>Tanaka</surname><given-names>MM</given-names></name></person-group><article-title>Trade-offs in resource allocation in the intracellular life-cycle of hepatitis C virus</article-title><source>J Theor Biol</source><year>2010</year><volume>267</volume><fpage>565</fpage><lpage>572</lpage><pub-id pub-id-type="doi">10.1016/j.jtbi.2010.09.031</pub-id><?supplied-pmid 20883700?><pub-id pub-id-type="pmid">20883700</pub-id></element-citation></ref><ref id="CR39"><label>39.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Nakabayashi</surname><given-names>J</given-names></name></person-group><article-title>A compartmentalization model of hepatitis C virus replication: an appropriate distribution of HCV RNA for the effective replication</article-title><source>J Theor Biol</source><year>2012</year><volume>300</volume><fpage>110</fpage><lpage>117</lpage><pub-id pub-id-type="doi">10.1016/j.jtbi.2012.01.023</pub-id><?supplied-pmid 22286015?><pub-id pub-id-type="pmid">22286015</pub-id></element-citation></ref><ref id="CR40"><label>40.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Binder</surname><given-names>M</given-names></name><name><surname>Sulaimanov</surname><given-names>N</given-names></name><name><surname>Clausznitzer</surname><given-names>D</given-names></name><name><surname>Schulze</surname><given-names>M</given-names></name><name><surname>H&#x000fc;ber</surname><given-names>CM</given-names></name><name><surname>Lenz</surname><given-names>SM</given-names></name><name><surname>Schl&#x000f6;der</surname><given-names>JP</given-names></name><name><surname>Trippler</surname><given-names>M</given-names></name><name><surname>Bartenschlager</surname><given-names>R</given-names></name><name><surname>Lohmann</surname><given-names>V</given-names></name><name><surname>Kaderali</surname><given-names>L</given-names></name></person-group><article-title>Replication vesicles are load- and choke-points in the hepatitis C virus lifecycle</article-title><source>PLoS Pathog</source><year>2013</year><volume>9</volume><fpage>e1003561</fpage><pub-id pub-id-type="doi">10.1371/journal.ppat.1003561</pub-id><?supplied-pmid 23990783?><pub-id pub-id-type="pmid">23990783</pub-id></element-citation></ref><ref id="CR41"><label>41.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Jonker</surname><given-names>DM</given-names></name><name><surname>Visser</surname><given-names>SA</given-names></name><name><surname>van der Graaf</surname><given-names>PH</given-names></name><name><surname>Voskuyl</surname><given-names>RA</given-names></name><name><surname>Danhof</surname><given-names>M</given-names></name></person-group><article-title>Towards a mechanism-based analysis of pharmacodynamic drug-drug interactions in vivo</article-title><source>Pharmacol Ther</source><year>2005</year><volume>106</volume><fpage>1</fpage><pub-id pub-id-type="doi">10.1016/j.pharmthera.2004.10.014</pub-id><?supplied-pmid 15781119?><pub-id pub-id-type="pmid">15781119</pub-id></element-citation></ref><ref id="CR42"><label>42.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kobayashi</surname><given-names>T</given-names></name><name><surname>Koizumi</surname><given-names>Y</given-names></name><name><surname>Takeuchi</surname><given-names>JS</given-names></name><name><surname>Misawa</surname><given-names>N</given-names></name><name><surname>Kimura</surname><given-names>Y</given-names></name><name><surname>Morita</surname><given-names>S</given-names></name><name><surname>Aihara</surname><given-names>K</given-names></name><name><surname>Koyanagi</surname><given-names>Y</given-names></name><name><surname>Iwami</surname><given-names>S</given-names></name><name><surname>Sato</surname><given-names>K</given-names></name></person-group><article-title>Quantification of Deaminase Activity-Dependent and -Independent Restriction of HIV-1 Replication Mediated by APOBEC3F and APOBEC3G through Experimental-Mathematical Investigation</article-title><source>J Virol</source><year>2014</year><volume>88</volume><fpage>5881</fpage><lpage>5887</lpage><pub-id pub-id-type="doi">10.1128/JVI.00062-14</pub-id><?supplied-pmid 24623435?><pub-id pub-id-type="pmid">24623435</pub-id></element-citation></ref><ref id="CR43"><label>43.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Keith</surname><given-names>CT</given-names></name><name><surname>Borisy</surname><given-names>AA</given-names></name><name><surname>Stockwell</surname><given-names>BR</given-names></name></person-group><article-title>Multicomponent therapeutics for networked systems</article-title><source>Nat Rev Drug Discov</source><year>2005</year><volume>4</volume><fpage>71</fpage><lpage>78</lpage><pub-id pub-id-type="doi">10.1038/nrd1609</pub-id><?supplied-pmid 15688074?><pub-id pub-id-type="pmid">15688074</pub-id></element-citation></ref><ref id="CR44"><label>44.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Fitzgerald</surname><given-names>JB</given-names></name><name><surname>Schoeberl</surname><given-names>B</given-names></name><name><surname>Nielsen</surname><given-names>UB</given-names></name><name><surname>Sorger</surname><given-names>PK</given-names></name></person-group><article-title>Systems biology and combination therapy in the quest for clinical efficacy</article-title><source>Nat Chem Biol</source><year>2006</year><volume>2</volume><fpage>458</fpage><lpage>466</lpage><pub-id pub-id-type="doi">10.1038/nchembio817</pub-id><?supplied-pmid 16921358?><pub-id pub-id-type="pmid">16921358</pub-id></element-citation></ref><ref id="CR45"><label>45.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Zimmermann</surname><given-names>GR</given-names></name><name><surname>Leh&#x000e1;r</surname><given-names>J</given-names></name><name><surname>Keith</surname><given-names>CT</given-names></name></person-group><article-title>Multi-target therapeutics: when the whole is greater than the sum of the parts</article-title><source>Drug Discov Today</source><year>2007</year><volume>12</volume><fpage>34</fpage><lpage>42</lpage><pub-id pub-id-type="doi">10.1016/j.drudis.2006.11.008</pub-id><?supplied-pmid 17198971?><pub-id pub-id-type="pmid">17198971</pub-id></element-citation></ref><ref id="CR46"><label>46.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kirouac</surname><given-names>DC</given-names></name><name><surname>Du</surname><given-names>JY</given-names></name><name><surname>Lahdenranta</surname><given-names>J</given-names></name><name><surname>Overland</surname><given-names>R</given-names></name><name><surname>Yarar</surname><given-names>D</given-names></name><name><surname>Paragas</surname><given-names>V</given-names></name><name><surname>Pace</surname><given-names>E</given-names></name><name><surname>McDonagh</surname><given-names>CF</given-names></name><name><surname>Nielsen</surname><given-names>UB</given-names></name><name><surname>Onsum</surname><given-names>MD</given-names></name></person-group><article-title>Computational modeling of ERBB2-amplified breast cancer identifies combined ErbB2/3 blockade as superior to the combination of MEK and AKT inhibitors</article-title><source>Sci Signal</source><year>2013</year><volume>6</volume><fpage>ra68</fpage><pub-id pub-id-type="doi">10.1126/scisignal.2004008</pub-id><?supplied-pmid 23943608?><pub-id pub-id-type="pmid">23943608</pub-id></element-citation></ref><ref id="CR47"><label>47.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Leh&#x000e1;r</surname><given-names>J</given-names></name><name><surname>Stockwell</surname><given-names>BR</given-names></name><name><surname>Giaever</surname><given-names>G</given-names></name><name><surname>Nislow</surname><given-names>C</given-names></name></person-group><article-title>Combination chemical genetics</article-title><source>Nat Chem Biol</source><year>2008</year><volume>4</volume><fpage>674</fpage><lpage>681</lpage><pub-id pub-id-type="doi">10.1038/nchembio.120</pub-id><?supplied-pmid 18936752?><pub-id pub-id-type="pmid">18936752</pub-id></element-citation></ref><ref id="CR48"><label>48.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Leh&#x000e1;r</surname><given-names>J</given-names></name><name><surname>Zimmermann</surname><given-names>GR</given-names></name><name><surname>Krueger</surname><given-names>AS</given-names></name><name><surname>Molnar</surname><given-names>RA</given-names></name><name><surname>Ledell</surname><given-names>JT</given-names></name><name><surname>Heilbut</surname><given-names>AM</given-names></name><name><surname>Short</surname><given-names>GF</given-names></name><name><surname>Giusti</surname><given-names>LC</given-names></name><name><surname>Nolan</surname><given-names>GP</given-names></name><name><surname>Magid</surname><given-names>OA</given-names></name><name><surname>Lee</surname><given-names>MS</given-names></name><name><surname>Borisy</surname><given-names>AA</given-names></name><name><surname>Stockwell</surname><given-names>BR</given-names></name><name><surname>Keith</surname><given-names>CT</given-names></name></person-group><article-title>Chemical combination effects predict connectivity in biological systems</article-title><source>Mol Syst Biol</source><year>2007</year><volume>3</volume><fpage>80</fpage><pub-id pub-id-type="doi">10.1038/msb4100116</pub-id><?supplied-pmid 17332758?><pub-id pub-id-type="pmid">17332758</pub-id></element-citation></ref><ref id="CR49"><label>49.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Owens</surname><given-names>CM</given-names></name><name><surname>Mawhinney</surname><given-names>C</given-names></name><name><surname>Grenier</surname><given-names>JM</given-names></name><name><surname>Altmeyer</surname><given-names>R</given-names></name><name><surname>Lee</surname><given-names>MS</given-names></name><name><surname>Borisy</surname><given-names>AA</given-names></name><name><surname>Leh&#x000e1;r</surname><given-names>J</given-names></name><name><surname>Johansen</surname><given-names>LM</given-names></name></person-group><article-title>Chemical combinations elucidate pathway interactions and regulation relevant to Hepatitis C replication</article-title><source>Mol Syst Biol</source><year>2010</year><volume>6</volume><fpage>375</fpage><pub-id pub-id-type="doi">10.1038/msb.2010.32</pub-id><?supplied-pmid 20531405?><pub-id pub-id-type="pmid">20531405</pub-id></element-citation></ref><ref id="CR50"><label>50.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Guedj</surname><given-names>J</given-names></name><name><surname>Perelson</surname><given-names>AS</given-names></name></person-group><article-title>Second-phase hepatitis C virus RNA decline during telaprevir-based therapy increases with drug effectiveness: implications for treatment duration</article-title><source>Hepatology</source><year>2011</year><volume>53</volume><fpage>1801</fpage><lpage>1808</lpage><pub-id pub-id-type="doi">10.1002/hep.24272</pub-id><?supplied-pmid 21384401?><pub-id pub-id-type="pmid">21384401</pub-id></element-citation></ref><ref id="CR51"><label>51.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Guedj</surname><given-names>J</given-names></name><name><surname>Neumann</surname><given-names>AU</given-names></name></person-group><article-title>Understanding hepatitis C viral dynamics with direct-acting antiviral agents due to the interplay between intracellular replication and cellular infection dynamics</article-title><source>J Theor Biol</source><year>2010</year><volume>267</volume><fpage>330</fpage><lpage>340</lpage><pub-id pub-id-type="doi">10.1016/j.jtbi.2010.08.036</pub-id><?supplied-pmid 20831874?><pub-id pub-id-type="pmid">20831874</pub-id></element-citation></ref><ref id="CR52"><label>52.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Guedj</surname><given-names>J</given-names></name><name><surname>Dahari</surname><given-names>H</given-names></name><name><surname>Rong</surname><given-names>L</given-names></name><name><surname>Sansone</surname><given-names>ND</given-names></name><name><surname>Nettles</surname><given-names>RE</given-names></name><name><surname>Cotler</surname><given-names>SJ</given-names></name><name><surname>Layden</surname><given-names>TJ</given-names></name><name><surname>Uprichard</surname><given-names>SL</given-names></name><name><surname>Perelson</surname><given-names>AS</given-names></name></person-group><article-title>Modeling shows that the NS5A inhibitor daclatasvir has two modes of action and yields a shorter estimate of the hepatitis C virus half-life</article-title><source>Proc Natl Acad Sci U S A</source><year>2013</year><volume>110</volume><fpage>3991</fpage><lpage>3996</lpage><pub-id pub-id-type="doi">10.1073/pnas.1203110110</pub-id><?supplied-pmid 23431163?><pub-id pub-id-type="pmid">23431163</pub-id></element-citation></ref><ref id="CR53"><label>53.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Rong</surname><given-names>L</given-names></name><name><surname>Guedj</surname><given-names>J</given-names></name><name><surname>Dahari</surname><given-names>H</given-names></name><name><surname>Coffield</surname><given-names>DJ</given-names></name><name><surname>Levi</surname><given-names>M</given-names></name><name><surname>Smith</surname><given-names>P</given-names></name><name><surname>Perelson</surname><given-names>AS</given-names></name></person-group><article-title>Analysis of hepatitis C virus decline during treatment with the protease inhibitor danoprevir using a multiscale model</article-title><source>PLoS Comput Biol</source><year>2013</year><volume>9</volume><fpage>e1002959</fpage><pub-id pub-id-type="doi">10.1371/journal.pcbi.1002959</pub-id><?supplied-pmid 23516348?><pub-id pub-id-type="pmid">23516348</pub-id></element-citation></ref><ref id="CR54"><label>54.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Rong</surname><given-names>L</given-names></name><name><surname>Perelson</surname><given-names>AS</given-names></name></person-group><article-title>Mathematical analysis of multiscale models for hepatitis C virus dynamics under therapy with direct-acting antiviral agents</article-title><source>Math Biosci</source><year>2013</year><volume>245</volume><fpage>22</fpage><lpage>30</lpage><pub-id pub-id-type="doi">10.1016/j.mbs.2013.04.012</pub-id><?supplied-pmid 23684949?><pub-id pub-id-type="pmid">23684949</pub-id></element-citation></ref><ref id="CR55"><label>55.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Rong</surname><given-names>L</given-names></name><name><surname>Dahari</surname><given-names>H</given-names></name><name><surname>Ribeiro</surname><given-names>RM</given-names></name><name><surname>Perelson</surname><given-names>AS</given-names></name></person-group><article-title>Rapid emergence of protease inhibitor resistance in hepatitis C virus</article-title><source>Sci Transl Med</source><year>2010</year><volume>2</volume><fpage>30ra32</fpage><pub-id pub-id-type="doi">10.1126/scitranslmed.3000544</pub-id><?supplied-pmid 20445200?><pub-id pub-id-type="pmid">20445200</pub-id></element-citation></ref></ref-list></back></article>